The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Acute Myeloid Leukemia Drugs Market Research Report 2025
Synopsis
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age.
The global Acute Myeloid Leukemia Drugs market was valued at US$ 1758 million in 2023 and is anticipated to reach US$ 3463.7 million by 2030, witnessing a CAGR of 10.2% during the forecast period 2024-2030.
The Acute Myeloid Leukemia (AML) Drugs market driver is the increasing incidence of AML globally, leading to a growing demand for effective treatments. The introduction of novel targeted therapies and immunotherapies has also driven market growth. However, challenges include the complexity of AML genetics, the need for personalized treatment approaches, and the high cost of newer therapies. Additionally, the competitive landscape and stringent regulatory requirements pose challenges for market players. Despite challenges, the AML Drugs market presents potential for growth as researchers and pharmaceutical companies continue to explore innovative treatments for this aggressive hematologic malignancy.
This report aims to provide a comprehensive presentation of the global market for Acute Myeloid Leukemia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Myeloid Leukemia Drugs.
Report Scope
The Acute Myeloid Leukemia Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acute Myeloid Leukemia Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Myeloid Leukemia Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ambit Biosciences Corporation
Bristol Myers Squibb
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Novartis
Eli Lilly and Company
Otsuka Holdings
Takeda Pharmaceuticals
Segment by Type
Chemotherapy
Targeted Therapy
Other
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Acute Myeloid Leukemia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Acute Myeloid Leukemia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age.
The global Acute Myeloid Leukemia Drugs market was valued at US$ 1758 million in 2023 and is anticipated to reach US$ 3463.7 million by 2030, witnessing a CAGR of 10.2% during the forecast period 2024-2030.
The Acute Myeloid Leukemia (AML) Drugs market driver is the increasing incidence of AML globally, leading to a growing demand for effective treatments. The introduction of novel targeted therapies and immunotherapies has also driven market growth. However, challenges include the complexity of AML genetics, the need for personalized treatment approaches, and the high cost of newer therapies. Additionally, the competitive landscape and stringent regulatory requirements pose challenges for market players. Despite challenges, the AML Drugs market presents potential for growth as researchers and pharmaceutical companies continue to explore innovative treatments for this aggressive hematologic malignancy.
This report aims to provide a comprehensive presentation of the global market for Acute Myeloid Leukemia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Myeloid Leukemia Drugs.
Report Scope
The Acute Myeloid Leukemia Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acute Myeloid Leukemia Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Myeloid Leukemia Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ambit Biosciences Corporation
Bristol Myers Squibb
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Novartis
Eli Lilly and Company
Otsuka Holdings
Takeda Pharmaceuticals
Segment by Type
Chemotherapy
Targeted Therapy
Other
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Acute Myeloid Leukemia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Acute Myeloid Leukemia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Acute Myeloid Leukemia Drugs Market Overview
1.1 Product Overview and Scope of Acute Myeloid Leukemia Drugs
1.2 Acute Myeloid Leukemia Drugs Segment by Type
1.2.1 Global Acute Myeloid Leukemia Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Other
1.3 Acute Myeloid Leukemia Drugs Segment by Application
1.3.1 Global Acute Myeloid Leukemia Drugs Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Acute Myeloid Leukemia Drugs Market Size Estimates and Forecasts
1.4.1 Global Acute Myeloid Leukemia Drugs Revenue 2019-2030
1.4.2 Global Acute Myeloid Leukemia Drugs Sales 2019-2030
1.4.3 Global Acute Myeloid Leukemia Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Acute Myeloid Leukemia Drugs Market Competition by Manufacturers
2.1 Global Acute Myeloid Leukemia Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Acute Myeloid Leukemia Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Acute Myeloid Leukemia Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Acute Myeloid Leukemia Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Acute Myeloid Leukemia Drugs, Product Type & Application
2.7 Acute Myeloid Leukemia Drugs Market Competitive Situation and Trends
2.7.1 Acute Myeloid Leukemia Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Acute Myeloid Leukemia Drugs Players Market Share by Revenue
2.7.3 Global Acute Myeloid Leukemia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Acute Myeloid Leukemia Drugs Retrospective Market Scenario by Region
3.1 Global Acute Myeloid Leukemia Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Acute Myeloid Leukemia Drugs Global Acute Myeloid Leukemia Drugs Sales by Region: 2019-2030
3.2.1 Global Acute Myeloid Leukemia Drugs Sales by Region: 2019-2024
3.2.2 Global Acute Myeloid Leukemia Drugs Sales by Region: 2025-2030
3.3 Global Acute Myeloid Leukemia Drugs Global Acute Myeloid Leukemia Drugs Revenue by Region: 2019-2030
3.3.1 Global Acute Myeloid Leukemia Drugs Revenue by Region: 2019-2024
3.3.2 Global Acute Myeloid Leukemia Drugs Revenue by Region: 2025-2030
3.4 North America Acute Myeloid Leukemia Drugs Market Facts & Figures by Country
3.4.1 North America Acute Myeloid Leukemia Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Acute Myeloid Leukemia Drugs Sales by Country (2019-2030)
3.4.3 North America Acute Myeloid Leukemia Drugs Revenue by Country (2019-2030)
3.4.4 the United States
3.4.5 Canada
3.5 Europe Acute Myeloid Leukemia Drugs Market Facts & Figures by Country
3.5.1 Europe Acute Myeloid Leukemia Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Acute Myeloid Leukemia Drugs Sales by Country (2019-2030)
3.5.3 Europe Acute Myeloid Leukemia Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Acute Myeloid Leukemia Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Acute Myeloid Leukemia Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Acute Myeloid Leukemia Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Acute Myeloid Leukemia Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Acute Myeloid Leukemia Drugs Market Facts & Figures by Country
3.7.1 Latin America Acute Myeloid Leukemia Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Acute Myeloid Leukemia Drugs Sales by Country (2019-2030)
3.7.3 Latin America Acute Myeloid Leukemia Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Acute Myeloid Leukemia Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Acute Myeloid Leukemia Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Acute Myeloid Leukemia Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Acute Myeloid Leukemia Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Acute Myeloid Leukemia Drugs Sales by Type (2019-2030)
4.1.1 Global Acute Myeloid Leukemia Drugs Sales by Type (2019-2024)
4.1.2 Global Acute Myeloid Leukemia Drugs Sales by Type (2025-2030)
4.1.3 Global Acute Myeloid Leukemia Drugs Sales Market Share by Type (2019-2030)
4.2 Global Acute Myeloid Leukemia Drugs Revenue by Type (2019-2030)
4.2.1 Global Acute Myeloid Leukemia Drugs Revenue by Type (2019-2024)
4.2.2 Global Acute Myeloid Leukemia Drugs Revenue by Type (2025-2030)
4.2.3 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Acute Myeloid Leukemia Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Acute Myeloid Leukemia Drugs Sales by Application (2019-2030)
5.1.1 Global Acute Myeloid Leukemia Drugs Sales by Application (2019-2024)
5.1.2 Global Acute Myeloid Leukemia Drugs Sales by Application (2025-2030)
5.1.3 Global Acute Myeloid Leukemia Drugs Sales Market Share by Application (2019-2030)
5.2 Global Acute Myeloid Leukemia Drugs Revenue by Application (2019-2030)
5.2.1 Global Acute Myeloid Leukemia Drugs Revenue by Application (2019-2024)
5.2.2 Global Acute Myeloid Leukemia Drugs Revenue by Application (2025-2030)
5.2.3 Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Acute Myeloid Leukemia Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Ambit Biosciences Corporation
6.1.1 Ambit Biosciences Corporation Corporation Information
6.1.2 Ambit Biosciences Corporation Description and Business Overview
6.1.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Product Portfolio
6.1.5 Ambit Biosciences Corporation Recent Developments/Updates
6.2 Bristol Myers Squibb
6.2.1 Bristol Myers Squibb Corporation Information
6.2.2 Bristol Myers Squibb Description and Business Overview
6.2.3 Bristol Myers Squibb Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bristol Myers Squibb Acute Myeloid Leukemia Drugs Product Portfolio
6.2.5 Bristol Myers Squibb Recent Developments/Updates
6.3 Cephalon
6.3.1 Cephalon Corporation Information
6.3.2 Cephalon Description and Business Overview
6.3.3 Cephalon Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Cephalon Acute Myeloid Leukemia Drugs Product Portfolio
6.3.5 Cephalon Recent Developments/Updates
6.4 Clavis Pharma
6.4.1 Clavis Pharma Corporation Information
6.4.2 Clavis Pharma Description and Business Overview
6.4.3 Clavis Pharma Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Clavis Pharma Acute Myeloid Leukemia Drugs Product Portfolio
6.4.5 Clavis Pharma Recent Developments/Updates
6.5 Eisai
6.5.1 Eisai Corporation Information
6.5.2 Eisai Description and Business Overview
6.5.3 Eisai Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Eisai Acute Myeloid Leukemia Drugs Product Portfolio
6.5.5 Eisai Recent Developments/Updates
6.6 Genzyme Corporation
6.6.1 Genzyme Corporation Corporation Information
6.6.2 Genzyme Corporation Description and Business Overview
6.6.3 Genzyme Corporation Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Genzyme Corporation Acute Myeloid Leukemia Drugs Product Portfolio
6.6.5 Genzyme Corporation Recent Developments/Updates
6.7 Sunesis Pharmaceuticals
6.6.1 Sunesis Pharmaceuticals Corporation Information
6.6.2 Sunesis Pharmaceuticals Description and Business Overview
6.6.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio
6.7.5 Sunesis Pharmaceuticals Recent Developments/Updates
6.8 Novartis
6.8.1 Novartis Corporation Information
6.8.2 Novartis Description and Business Overview
6.8.3 Novartis Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Novartis Acute Myeloid Leukemia Drugs Product Portfolio
6.8.5 Novartis Recent Developments/Updates
6.9 Eli Lilly and Company
6.9.1 Eli Lilly and Company Corporation Information
6.9.2 Eli Lilly and Company Description and Business Overview
6.9.3 Eli Lilly and Company Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Eli Lilly and Company Acute Myeloid Leukemia Drugs Product Portfolio
6.9.5 Eli Lilly and Company Recent Developments/Updates
6.10 Otsuka Holdings
6.10.1 Otsuka Holdings Corporation Information
6.10.2 Otsuka Holdings Description and Business Overview
6.10.3 Otsuka Holdings Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Otsuka Holdings Acute Myeloid Leukemia Drugs Product Portfolio
6.10.5 Otsuka Holdings Recent Developments/Updates
6.11 Takeda Pharmaceuticals
6.11.1 Takeda Pharmaceuticals Corporation Information
6.11.2 Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Description and Business Overview
6.11.3 Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Takeda Pharmaceuticals Acute Myeloid Leukemia Drugs Product Portfolio
6.11.5 Takeda Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Acute Myeloid Leukemia Drugs Industry Chain Analysis
7.2 Acute Myeloid Leukemia Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Acute Myeloid Leukemia Drugs Production Mode & Process
7.4 Acute Myeloid Leukemia Drugs Sales and Marketing
7.4.1 Acute Myeloid Leukemia Drugs Sales Channels
7.4.2 Acute Myeloid Leukemia Drugs Distributors
7.5 Acute Myeloid Leukemia Drugs Customers
8 Acute Myeloid Leukemia Drugs Market Dynamics
8.1 Acute Myeloid Leukemia Drugs Industry Trends
8.2 Acute Myeloid Leukemia Drugs Market Drivers
8.3 Acute Myeloid Leukemia Drugs Market Challenges
8.4 Acute Myeloid Leukemia Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
